Document Detail


Use of amifostine in the therapy of osteosarcoma in children and adolescents.
MedLine Citation:
PMID:  11990304     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. In this study, 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. The chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m2), carboplatin (500 mg/m2), and doxorubicin (60 mg/m2), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m2), ifosfamide/doxorubicin, carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) infusions and two to five episodes occurred in 51 (28%) infusions, and no patient had grade 4 toxicity. There was no difference between the two groups regarding renal toxicity (creatinine clearance). Neutropenia and leukopenia were significantly less frequent in the amifostine group. No difference was observed in platelet and hearing toxicities. Amifostine was well tolerated in doses of 740 mg/m2 in children and adolescents, and myelotoxicity was less severe in the amifostine group. This was a pilot study for further evaluation in a larger randomized trial.
Authors:
Antonio Sergio Petrilli; Delma Tostes Oliveira; Valeria Cortez Ginani; Rita Kechichian; Andrea Dishtchekenian; Werthon de Medeiros Roque Filho; Cristiana Tanaka; Carlo Gonçalves Dias; Maria do Rosário Dias de Oliveira Latorre; Algemir Lunardi Brunetto; Hedilene Cardoso; Maria Teresa Almeida; Beatriz de Camargo
Related Documents :
1606064 - Treatment of advanced ovarian cancer: 10 years of experience.
16098244 - Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unre...
25208624 - Significance of early prostate-specific antigen values after salvage radiotherapy in re...
16282244 - Recombinant human angiostatin (rhangiostatin) in combination with paclitaxel and carbop...
6687624 - Lymphoblastic lymphoma: late relapse in childhood.
15760404 - The impact of pre-operative loco-regional therapy on outcome after liver transplantatio...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  24     ISSN:  1077-4114     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:    2002 Mar-Apr
Date Detail:
Created Date:  2002-05-06     Completed Date:  2002-05-23     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  188-91     Citation Subset:  IM    
Affiliation:
Pediatric Oncology Institute, Department of Pediatrics-Escola Paulista de Medicina, Universidade Federal de São Paulo, SP, Brazil. iopepm@dialdata.com.br
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Amifostine / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / drug therapy*,  pathology,  surgery
Carboplatin / administration & dosage,  adverse effects
Child
Child, Preschool
Cisplatin / administration & dosage,  adverse effects
Doxorubicin / administration & dosage,  adverse effects
Female
Humans
Ifosfamide / administration & dosage,  adverse effects
Leukopenia / chemically induced
Male
Neutropenia / chemically induced
Osteosarcoma / drug therapy*,  pathology,  surgery
Pilot Projects
Radiation-Protective Agents / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Radiation-Protective Agents; 15663-27-1/Cisplatin; 20537-88-6/Amifostine; 23214-92-8/Doxorubicin; 3778-73-2/Ifosfamide; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute...
Next Document:  Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Res...